Business Development Archives | Report Store

Novartis’ Zolgensma Had Manipulated Data In Application, US FDA Says

The gene therapy Zolgensma will remain on the market, but Novartis and subsidiary AveXis Inc. may face civil or criminal action after revelations by the FDA that data used for approval had been manipulated. In fact, the drug giant knew about the problem months before Zolgensma was approved and said nothing. Learn what happened, why the FDA still asserts confidence in its approval of Zolgensma, and what these events could mean to Novartis and the gene therapy industry moving forward.

Business Development

Business Development

Novartis’ Zolgensma Had Manipulated Data In Application, US FDA Says

Novartis CEO Explains Delay In Telling US FDA About Zolgensma Data Fraud: We Wanted To Understand It First

Reckitt Invests In AI Symptom Checker To ‘Unlock Self-Care’

GSK And Pfizer Assemble Consumer Healthcare Leadership Team As JV Closes

House Committee Hearing Shows How Talc/Asbestos Concerns Could Be Impetus For Cosmetics Reform

The Knowledge Within: An Interview With Merck KGaA’s R&D Chief

How Roche Won The Bidding Battle For Spark

Gene Therapy Investment At All Time High, Commercialization Challenges Noted

BioMarin Is Carrying The Biggest Target On Its Back, Morningstar Says

Modernizing FDA’s Supplement Industry Regulation Mapped Out In Five-Point Plan

What Does 2019 Hold For Biopharma?

J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven And Lilly

J.P. Morgan 2019: Industry Throws A Bonanza, With An Elephant In The Room

J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven, Lilly And FDA’s Gottlieb

The Next New Thing In FDA Inspections: Poor Root Cause Investigations